Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show

Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show
A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in men with metastatic castration-resistant prostate cancer (mCRPC), preliminary results from an ongoing Phase 1/2 trial show. The findings were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting, held recently in Anaheim, Calif. The presentation, titled “Interim Results of a Phase I/II Prospective Dose Escalation Trial Evaluating Safety and Efficacy of Combination 177Lu PSMA 617 and NOX66 in Men with mCRPC Post Androgen Signalling Inhibition and 2 Lines of Taxane Chemotherapy (LuPIN Trial),” highlighted the study's positive interim clinical data. Treatment with the targeted radiotherapy LuPSMA alone has proven safe and effective in prostate cancer patients. However, some men do not respond to the treatment, and those who do have limited responses in duration. Veyonda (formerly known as NOX66) is a kind of immunotherapy that works to increase the number of cancer cells killed by chemotherapy and radiation therapy. It does so by activating the innat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *